Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

被引：0
|
作者：
Tetsu Hayashida
Hiromitsu Jinno
Katsuaki Mori
Hiroki Sato
Akira Matsui
Takashi Sakurai
Hiroaki Hattori
Shin Takayama
Masahiro Wada
Maiko Takahashi
Hirohito Seki
Tomoko Seki
Aiko Nagayama
Akiko Matsumoto
Yuko Kitagawa
机构：
[1] Keio University School of Medicine,Department of Surgery
[2] Teikyo University School of Medicine,Department of Surgery
[3] Hino Municipal Hospital,Department of Surgery
[4] Mito Red Cross Hospital,Department of Surgery
[5] National Hospital Organization Tokyo Medical Center,Department of Surgery
[6] JCHO Saitama Medical Center,Division of Surgery
[7] Federation of National Public Service Personnel Mutual Aid Associations,Department of Surgery
[8] Tachikawa Hospital,Department of surgery
[9] Tokyo Dental College Ichikawa General Hospital,Department of Surgery
[10] Sanokousei general hospital,undefined
来源：
BMC Cancer | / 18卷
关键词：
Breast cancer; Eribulin; Phase II trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] A Single-arm, Multicenter, Open-label Phase 2 Study of Lapatinib as the Second-line Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma
    Wuelfing, Christian
    Machiels, Jean-Pascal H.
    Richel, Dirk J.
    Grimm, Marc-Oliver
    Treiber, Uwe
    De Groot, Marco R.
    Beuzeboc, Philippe
    Parikh, Roma
    Petavy, Frank
    El-Hariry, Iman A.
    CANCER, 2009, 115 (13) : 2881 - 2890
  • [32] Nab-paclitaxel combined with cadonilimab (AK104) as second-line treatment for advanced gastric cancer: protocol for a phase II prospective, multicenter, single-arm clinical trial
    Wei, Jing
    Zhang, Pengfei
    Hu, Qiancheng
    Cheng, Xiaolong
    Shen, Chaoyong
    Chen, Zhixin
    Zhuang, Wen
    Yin, Yuan
    Zhang, Bo
    Gou, Hongfeng
    Yang, Kun
    Bi, Feng
    Liu, Ming
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [33] A randomized phase II trial of carboplatin with or without nivolumab in first- or second-line metastatic TNBC.
    Garrido-Castro, Ana Christina
    Barry, William Thomas
    Traina, Tiffany A.
    Wesolowski, Robert
    Tung, Nadine M.
    Keenan, Tanya
    Van Allen, Eliezer Mendel
    Lin, Nancy U.
    Winer, Eric P.
    Krop, Ian E.
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Quality of life results from a phase 2, multicenter, single-arm study of eribulin mesylate plus trastuzumab as first-line therapy for locally recurrent or metastatic HER2+breast cancer
    Schwartzberg, Lee
    Wilks, Sharon
    Puhalla, Shannon
    O'Shaughnessy, Joyce
    Berrak, Erhan
    Song, James
    Cox, David
    Vahdat, Linda
    CANCER RESEARCH, 2015, 75
  • [35] Bevacizumab and pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer: A multicenter, single-arm phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)
    Rochlitz, C.
    Spirig, C.
    Ruhstaller, T.
    Suter, T.
    Buehlmann, M.
    Fehr, M.
    Schoenenberger, A.
    Lerch, S.
    Mayer, M.
    Zaman, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+locally recurrent or metastatic breast cancer (MBC): Results from a phase II, single-arm, multicenter study.
    Puhalla, Shannon
    Wilks, Sharon
    Brufsky, Adam
    O'Shaughnessy, Joyce
    Schwartzberg, Lee Steven
    Berrak, Erhan
    Song, James
    Cox, David
    Vandat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] A phase II, multicenter, single-arm trial of CV301 plus atezolizumab (Atezo) in locally advanced (unresectable) or metastatic urothelial cancer (UC).
    Sonpavde, Guru
    Maughan, Benjamin Louis
    Wei, Xiao X.
    McGregor, Bradley Alexander
    Kilbridge, Kerry L.
    Lee, Richard J.
    Yu, Evan
    Schweizer, Michael Thomas
    Montgomery, Robert B.
    Cheng, Heather H.
    Hsieh, Andrew Caleb
    Birhiray, Ruemu E.
    Gabrail, Nashat Y.
    Nemunaitis, John J.
    Rezazadeh, Arash
    Van Veldhuizen, Peter J.
    Vogelzang, Nicholas J.
    Heery, Christopher Ryan
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [38] A phase II trial of temsirolimus in second-line metastatic urothelial cancer
    Gerullis, H.
    Eimer, C.
    Ecke, T. H.
    Georgas, E.
    Freitas, C.
    Kastenholz, S.
    Arndt, C.
    Heusch, C.
    Otto, T.
    MEDICAL ONCOLOGY, 2012, 29 (04) : 2870 - 2876
  • [39] A phase II trial of temsirolimus in second-line metastatic urothelial cancer
    H. Gerullis
    C. Eimer
    T. H. Ecke
    E. Georgas
    C. Freitas
    S. Kastenholz
    C. Arndt
    C. Heusch
    T. Otto
    Medical Oncology, 2012, 29 : 2870 - 2876
  • [40] Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial
    Zhang, Changgong
    Chen, Jianhua
    Wu, Huijuan
    Wang, Jun
    Gao, Liying
    Zhao, Jun
    Sun, Yan
    Jia, Zhongyao
    Mu, Xinlin
    Bai, Chunmei
    Wang, Rui
    Wu, Kailiang
    Liu, Qiang
    Shi, Yuankai
    CANCER PATHOGENESIS AND THERAPY, 2024, 2 (04): : 268 - 275
12345